<DOC>
	<DOCNO>NCT01165125</DOCNO>
	<brief_summary>A randomized two-way crossover study determine whether concomitant administration CYP P450 3A4 inhibitor ketoconazole fluticasone furoate/GW642444M combination significantly increase systemic effect exposure repeat dose fluticasone furoate and/or GW642444 healthy subject . Key assessment include blood potassium , heart rate , blood pressure , QTc , serum cortisol pharmacokinetic parameter , safety include vital sign , ECGs , adverse event monitor laboratory safety test , include blood glucose .</brief_summary>
	<brief_title>A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder Ketoconazole</brief_title>
	<detailed_description>This single centre , randomize , double-blind ( respect ketoconazole ) , two-way cross-over study healthy male female subject . Subjects attend screen visit within 28 day prior first treatment period . There two study period , consist 14 day . Ketoconazole match placebo administer 11 day fluticasone furoate/GW642444M inhalation powder co-administered Days 5-11 . During period subject require report unit Day -1 remain 1 hour post-dosing ketoconazole placebo Day 1 . Subjects return unit morning Day 2 Day 4 dose ketoconazole placebo . Subjects return even Day 4 leave unit morning Day 6 ( 2 night ) . Subjects return unit morning Day 7 Day 10 dose pre-fluticasone furoate/GW642444M dose safety assessment . Subjects return even Day 10 leave unit morning Day 12 ( 2 night ) . Subjects make two outpatient visit , one evening Day 12 one morning Day 13 , complete study related procedure . The two treatment period separate washout least 7 day 14 day . Pharmacodynamic profile potassium , heart rate , QTc , blood pressure serum cortisol take Day 11 fluticasone furoate GW642444 pharmacokinetic profile Days 5 11 . Safety assessment include vital sign , ECGs , adverse event monitor laboratory safety test , plus blood glucose blood potassium profile Day 5 .</detailed_description>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>1 . Healthy male female 18 64 year age inclusive 2 . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method Section 8.1 wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Childbearing potential agrees use one contraception method list Section 8.1 appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception completion followup visit . 3 . Body mass index within range 18.529.0 kg/m2 inclusive . 4 . Subjects current nonsmoker , use tobacco product 12 month period precede screen visit , pack history &lt; /= 5 pack year . 5 . AST , ALT , alkaline phosphatase bilirubin &lt; /= 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . 6 . No significant abnormality 12lead ECG screening , include follow specific requirement : QTcF &lt; 450 msec 7 . No clinically significant abnormality Holter ECG screen . 8 . FEV1 &gt; /= 85 % predict screening . 9 . Capable give write informed consent , include compliance requirement restriction list consent form . 10 . Able satisfactorily use dry powder inhaler . 1 . As result medical interview , physical examination screen investigation , principal investigator delegate physician deems subject unsuitable study . Subjects must systolic blood pressure 145 mmHg diastolic pressure 85 mmHg unless Investigator confirm satisfactory age . 2 . The subject history breathing problem adult life ( i.e . history asthmatic symptomatology ) . 3 . Pregnant female determine positive serum hCG test screen positive serum/urine hCG test prior dose . 4 . Lactating female . 5 . The subject treat diagnosed depression within six month screen history significant psychiatric illness . 6 . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . 7 . Subjects suffer low respiratory tract infection within 4 week screen visit . 8 . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . 9 . Any adverse reaction include immediate delay hypersensitivity betaagonist , sympathomimetic drug , intranasal , inhaled systemic corticosteroid therapy . Known suspected sensitivity constituent new powder inhaler ( ie lactose magnesium stearate ) 10 . History milk protein allergy . 11 . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . 12 . The subject take oral corticosteroid le 8 week screen visit . 13 . The subject take inhaled , intranasal topical steroid le 4 week screen visit . 14 . History alcohol/drug abuse dependence within 12 month study . Abuse alcohol define average weekly intake great 21 unit average daily intake great 3 unit ( male ) define average weekly intake great 14 unit average daily intake great 2 unit ( female ) . 15 . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 3 month , 5 halflives twice duration biological effect investigational product ( whichever longer ) . 16 . Exposure four new chemical entity within 12 month prior first dose day . 17 . Where participation study would result donation blood blood product excess 500 mL within 3 month start trial . 18 . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . 19 . The subject test positive HIV antibody . 20 . A positive prestudy urine drug screen randomly test study . 21 . Positive carbon monoxide ( CO ) alcohol breath test screen admission Unit . 22 . Consumption seville orange , pomelo ( member grapefruit family ) grapefruit juice 7 day prior first dose study medication . 23 . Unwillingness inability follow procedure outline protocol . 24 . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pharmacodynamics</keyword>
	<keyword>drug interaction</keyword>
	<keyword>ketoconazole</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Fluticasone furoate</keyword>
	<keyword>GW642444</keyword>
</DOC>